OctoPlus announces change in Executive Board
(Thomson Reuters ONE) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO)announces today that Joost Holthuis has decided to step down as ChiefScientific Officer after successfully leading the Company for almost15 years since he founded OctoPlus in 1995. The Company will continueto have access to Mr. Holthuis' experience and expertise on aconsultancy basis.Simon Sturge, CEO of OctoPlus comments: "On behalf of the ExecutiveBoard and the Board of Supervisory Directors, I would like to thankJoost for his commitment and the outstanding achievements he has madein the development of the Company throughout the 15 years that theCompany has existed. He has made an invaluable contribution to theorganisation we are today, growing from a start-up service providerto an internationally acknowledged centre of excellence in the areasof formulation development and controlled release drug delivery."Joost Holthuis comments: "It has been a great pleasure for me to havebeen part of this company. After 15 years it is now time for me toexplore other interests. I trust the current management team to takethe Company forward and I am confident that OctoPlus has a greatfuture ahead of itself."For further information, please contact:Rianne Roukema, Corporate Communications: telephone number +31 (71)524 1071 or send an e-mail to Investor Relations at IR(at)octoplus.nl.About OctoPlusOctoPlus is a product-oriented biopharmaceutical company committed tothe creation of improved pharmaceutical products that are based onOctoPlus' proprietary drug delivery technologies and have fewer sideeffects, improved patient convenience and a better efficacy/safetybalance than existing therapies. Rather than seeking to discovernovel drug candidates through early stage research activities,OctoPlus focuses on the development of long-acting, controlledrelease versions of known protein therapeutics, other drugs, andvaccines on behalf of its clients.The clinically most advanced product incorporating our technology isBiolex Therapeutics' lead product Locteron®, a controlled releaseformulation of interferon alpha for the treatment of chronichepatitis C. Locteron is being manufactured for Biolex Therapeuticsby OctoPlus and is currently in Phase IIb clinical studies.In addition, OctoPlus is a leading European provider of advanced drugformulation and clinical scale manufacturing services to thepharmaceutical and biotechnology industries, with a focus ondifficult-to-formulate active pharmaceutical ingredients.OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under thesymbol OCTO. For more information about OctoPlus, please visit ourwebsite www.octoplus.nl.This document may contain certain forward-looking statements relatingto the business, financial performance and results of OctoPlus andthe industry in which it operates. These statements are based onOctoPlus' current plans, estimates and projections, as well as itsexpectations of external conditions and events. In particular thewords "expect", "anticipate", "predict", "estimate", "project","plan", "may", "should", "would", "will", "intend", "believe" andsimilar expressions are intended to identify forward-lookingstatements. We caution investors that a number of important factors,and the inherent risks and uncertainties that such statementsinvolve, could cause actual results or outcomes to differ materiallyfrom those expressed in any forward-looking statements. In the eventof any inconsistency between an English version and a Dutch versionof this document, the English version will prevail over the Dutchversion.http://hugin.info/137076/R/1337032/318384.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 26.08.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 5085
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 367 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus announces change in Executive Board"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
